{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Amir Prior"}, {"accession": "MS:1000589", "name": "contact email", "value": "amir.prior@weizmann.ac.il"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Weizmann Institute of Science"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Ravid Straussman"}, {"accession": "MS:1000589", "name": "contact email", "value": "Ravidst@weizmann.ac.il"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Molecular Cell Biology, Weizmann institute of Science, Israel"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_A5_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_A5_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_A5_3_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B13_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B13_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B13_3_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B24_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B24_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B24_3_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B6_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B6_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_B6_3_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_SBA14_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_SBA14_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_SBA14_3_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_WP_1_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_WP_2_phos_080119.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HFX_8619_RST_WP_3_phos_080119.raw"}, {"accession": "MS:1002860", "name": "Gel image file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HeatMap_non_imputated.png"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/Phospho (STY)Sites.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/msms.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/allPeptides.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/PD_8619_18samples_PhosphoSTY_11Feb2019.sps"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/mzRange.txt"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/peptides.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/peptides_enrichment_rate_13Feb2019.xlsx"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/msmsScans.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/tables.pdf"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/summary.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/evidence.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/modificationSpecificPeptides.txt"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/proteinGroups.txt"}, {"accession": "MS:1002860", "name": "Gel image file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/HeatMap.png"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/msScans.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/Raw_data_before_normalization.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/parameters.txt"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857/Oxidation (M)Sites.txt"}], "description": "Stochastic transition of cancer cells between drug-sensitive and drug-tolerant persister phenotypes has been proposed to play a key role in non-genetic resistance to therapy. Yet, we show here that cancer cells actually possess a highly stable inherited chance to persist (CTP) during therapy. This CTP is non-stochastic, determined pre-treatment, and has a unimodal distribution ranging from 0 to almost 100%. Importantly, CTP is drug-specific. We found that differential serine/threonine phosphorylation of the insulin receptor substrate 1 (IRS1) protein determines the CTP of lung and of head and neck cancer cells under EGFR inhibition, both in vitro and in vivo. Indeed, the first-in-class IRS1 inhibitor NT219 was highly synergistic with anti-EGFR therapy across multiple in vitro and in vivo models. Elucidation of drug-specific mechanisms that determine the degree and stability of cellular CTP may establish a framework for the elimination of cancer persisters, using novel rationally designed drug combinations.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD026857"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD026857"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD026857"}], "instruments": [{"accession": "MS:1002523", "name": "Q Exactive HF"}, {"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Cancer, drug tolerant cells, cancer peristers, drug resistance, EGFR inhibition, IRS1, NSCLC"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy"}